keyword
MENU ▼
Read by QxMD icon Read
search

Psma

keyword
https://www.readbyqxmd.com/read/28445962/psma-homing-dsrna-chimeric-protein-vector-kills-prostate-cancer-cells-and-activates-anti-tumor-bystander-responses
#1
Yael Langut, Nufar Edinger, Efrat Flashner-Abramson, Naomi Melamed-Book, Mario Lebendiker, Yael Levi-Kalisman, Shoshana Klein, Alexander Levitzki
The treatment of metastatic androgen-resistant prostate cancer remains a challenge. We describe a protein vector that selectively delivers synthetic dsRNA, polyinosinic/polycytidylic acid (polyIC), to prostate tumors by targeting prostate specific membrane antigen (PSMA), which is overexpressed on the surface of prostate cancer cells.The chimeric protein is built from the double stranded RNA (dsRNA) binding domain of PKR tethered to a single chain anti-PSMA antibody. When complexed with polyIC, the chimera demonstrates selective and efficient killing of prostate cancer cells...
April 11, 2017: Oncotarget
https://www.readbyqxmd.com/read/28445813/microfluidic-integrated-patterned-ito-immunosensor-for-rapid-detection-of-prostate-specific-membrane-antigen-biomarker-in-prostate-cancer
#2
Rajesh Seenivasan, Chandra K Singh, Jay W Warrick, Nihal Ahmad, Sundaram Gunasekaran
An optically transparent patterned indium tin oxide (ITO) three-electrode sensor integrated with a microfluidic channel was designed for label-free immunosensing of prostate-specific membrane antigen (PSMA), a prostate cancer (PCa) biomarker, expressed on prostate tissue and circulating tumor cells but also found in serum. The sensor relies on cysteamine capped gold nanoparticles (N-AuNPs) covalently linked with anti-PSMA antibody (Ab) for target specificity. A polydimethylsiloxane (PDMS) microfluidic channel is used to efficiently and reproducibly introduce sample containing soluble proteins/cells to the sensor...
April 11, 2017: Biosensors & Bioelectronics
https://www.readbyqxmd.com/read/28440324/lutetium-177-labelled-anti-prostate-specific-membrane-antigen-antibody-and-ligands-for-the-treatment-of-metastatic-castrate-resistant-prostate-cancer-a-systematic-review-and-meta-analysis
#3
R J S Calopedos, V Chalasani, R Asher, L Emmett, H H Woo
BACKGROUND: Promising therapeutic results of the prostate-specific membrane antigen (PSMA) ligand have been shown when labelling with lutetium-177 ((177)Lu). We performed a systematic review and meta-analysis to assess the therapeutic response of (177)Lu-PSMA in the treatment of metastatic castration-resistant prostate cancer (mCRPC). METHODS: A systematic review was conducted using electronic databases up to December 2016. Two reviewers independently extracted data and assessed methodological quality...
April 25, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28438628/diagnostic-accuracy-of-64-cu-psma-pet-ct-for-primary-lymph-node-staging-of-intermediate-to-high-risk-prostate-cancer-our-preliminary-experience
#4
Francesco Cantiello, Vincenzo Gangemi, Giuseppe Lucio Cascini, Ferdinando Calabria, Marco Moschini, Matteo Ferro, Gennaro Musi, Salvatore Butticè, Andrea Salonia, Alberto Briganti, Rocco Damiano
OBJECTIVE: To assess the diagnostic accuracy of (64)Copper Prostate-Specific Membrane Antigen ((64)Cu PSMA) positron emission tomography/computed tomography (PET/CT) in the primary lymph node (LN) staging of a selected cohort of intermediate-high risk Prostate Cancer (PCa) patients. MATERIALS AND METHODS: An observational prospective study was performed in 23 patients with intermediate-high risk PCa, who underwent (64)Cu-PSMA PET/CT for local and lymph nodal staging before laparoscopic radical prostatectomy (LRP) with an extended pelvic LN dissection...
April 21, 2017: Urology
https://www.readbyqxmd.com/read/28438468/clinical-results-and-economic-considerations-of-68-ga-psma-and-radiolabeled-choline-in-prostate-cancer
#5
Laura Evangelista, Maria Giuseppina Bonavina, Emilio Bombardieri
In recent years there was an impressive improvement in the options for the management of patients with prostate cancer. Nuclear Medicine has significantly enriched its diagnostic options, both in radiopharmacy and in instrumentation, in order to accurately target prostatic cancer cells, thus rendering the physicians able to adopt the best therapeutic strategy. In the present analysis, we have evaluated the available published data about 68Ga-PSMA and radio-labeled choline, two radiopharmaceutical agents for positron emission tomography/computed tomography (PET/CT) examination, by reporting clinical information and considering data about legal, economic and organization aspects...
April 5, 2017: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/28434181/management-options-for-biochemically-recurrent-prostate-cancer
#6
REVIEW
Farhad Fakhrejahani, Ravi A Madan, William L Dahut
Prostate cancer is the most common solid tumor malignancy in men worldwide. Treatment with surgery and radiation can be curative in organ-confined disease. Unfortunately, about one third of men develop biochemically recurrent disease based only on rising prostate-specific antigen (PSA) in the absence of visible disease on conventional imaging. For these patients with biochemical recurrent prostate cancer, there is no uniform guideline for subsequent management. Based on available data, it seems prudent that biochemical recurrent prostate cancer should initially be evaluated for salvage radiation or prostatectomy, with curative intent...
May 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28427152/radioligand-therapy-of-metastatic-prostate-cancer-using-177lu-psma-617-after-radiation-exposure-to-223ra-dichloride
#7
Hojjat Ahmadzadehfar, Stefanie Zimbelmann, Anna Yordanova, Rolf Fimmers, Stefan Kürpig, Elisabeth Eppard, Florian C Gaertner, Xiao Wei, Stefan Hauser, Markus Essler
Radioligand therapy with 177Lu-PSMA-617 is an innovative and effective therapy for castrate-resistant metastatic prostate cancer patients. For patients with symptomatic bone metastases without visceral metastases, the guidelines recommend radionuclide therapy with 223Ra-dichloride as a single therapeutic agent or in combination with hormone therapy. The aim of this study was to evaluate the safety of repeated cycles of 177Lu-PSMA-617 after exposure to more cycles of 223Ra. Forty-nine patients were treated with three cycles of Lu-PSMA-617 divided into two groups subjected to a history of therapy with 223Ra...
February 25, 2017: Oncotarget
https://www.readbyqxmd.com/read/28408532/-68-ga-thp-psma-a-pet-imaging-agent-for-prostate-cancer-offering-rapid-room-temperature-one-step-kit-based-radiolabeling
#8
Jennifer D Young, Vincenzo Abbate, Cinzia Imberti, Levente K Meszaros, Michelle T Ma, Samantha Y A Terry, Robert C Hider, Greg E Mullen, Philip J Blower
The clinical impact and accessibility of (68)Ga tracers for the prostate-specific membrane antigen (PSMA) and other targets would be greatly enhanced by the availability of a simple, one-step kit-based labeling process. Radiopharmacy staff are accustomed to such procedures in the daily preparation of (99m)Tc radiopharmaceuticals. Currently, chelating agents used in (68)Ga radiopharmaceuticals do not meet this ideal. AIM: To develop and evaluate preclinically a (68)Ga radiotracer for imaging PSMA expression that could be radiolabeled simply by addition of (68)Ga generator eluate to a cold kit...
April 13, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28408531/-68-ga-psma-11-pet-ct-interobserver-agreement-for-prostate-cancer-assessments-an-international-multicenter-prospective-study
#9
Wolfgang Peter Fendler, Jeremie Calais, Martin Allen-Auerbach, Christina Bluemel, Nina Eberhardt, Louise Emmett, Pawan Gupta, Markus Hartenbach, Thomas A Hope, Shozo Okamoto, Christian Helmut Pfob, Thorsten D Pöppel, Christoph Rischpler, Sarah Schwarzenböck, Vanessa Stebner, Marcus Unterrainer, Helle D Zacho, Tobias Maurer, Christian Gratzke, Alexander Crispin, Johannes Czernin, Ken Herrmann, Matthias Eiber
Background: The interobserver agreement for (68)Ga-PSMA-11 Positron Emission Tomography/Computed Tomography (PET/CT) study interpretations in patients with prostate cancer is unknown. Methods:(68)Ga-PSMA-11 PET/CT was performed in 50 patients with prostate cancer for biochemical recurrence (n = 25), primary diagnosis (n = 10), biochemical persistence after primary therapy (n = 5) or staging of known metastatic disease (n = 10). Images were reviewed by 16 observers who used a standardized approach for interpretation of local (T), nodal (N), bone (Mb), or visceral (Mc) involvement...
April 13, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28408529/targeted-alpha-therapy-of-mcrpc-with-225-actinium-psma-617-dosimetry-estimate-and-empirical-dose-finding
#10
Clemens Kratochwil, Frank Bruchertseifer, Hendrik Rathke, Marcus Bronzel, Christos Apostolidis, Wilko Weichert, Uwe Haberkorn, Frederick Lars Giesel, Alfred Morgenstern
To develop a treatment protocol for (225)Ac-PSMA-617 alpha-radiation therapy in advanced stage, metastatic castration-resistant prostate cancer patients with PSMA-positive tumor phenotype. Methods: A dosimetry estimate was calculated based on time-activity-curves derived from serially performed (177)Lu-PSMA-617 scans extrapolated to the physical half-life of (225)Ac, assuming instant decay of instable daughter nuclides. Salvage therapies empirically conducted with 50kBq/kg (n = 4), 100kBq/kg (n = 4), 150kBq/kg (n = 2), 200kBq/kg (n = 4) (225)Ac-PSMA-617 were evaluated retrospectively regarding toxicity and treatment response...
April 13, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28408526/gallium-68-or-fluorine-18-for-prostate-cancer-imaging
#11
Claudia Kesch, Clemens Kratochwil, Walter Mier, Klaus Kopka, Frederik L Giesel
The introduction of prostate specific membrane antigen (PSMA)-positron emission tomography (PET) using (68)Ga revolutionized prostate cancer imaging. Outperforming standard imaging, it allows complete staging of the local tumor and possible lymph nodes, visceral or bone metastases with high accuracy in only one examination (1,2). Sensitivities of 66% and specificities of 99% were observed for primary lymph node staging. Moreover, it has become an excellent staging tool for recurrent prostate cancer even at early stage and low PSA levels...
April 13, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28404896/retargeting-of-t-lymphocytes-to-psca-or-psma-positive-prostate-cancer-cells-using-the-novel-modular-chimeric-antigen-receptor-platform-technology-unicar
#12
Anja Feldmann, Claudia Arndt, Ralf Bergmann, Simon Loff, Marc Cartellieri, Dominik Bachmann, Roberta Aliperta, Mirjam Hetzenecker, Florian Ludwig, Susann Albert, Pauline Ziller-Walter, Alexandra Kegler, Stefanie Koristka, Sebastian Gärtner, Marc Schmitz, Armin Ehninger, Gerhard Ehninger, Jens Pietzsch, Jörg Steinbach, Michael Bachmann
New treatment options especially of solid tumors including for metastasized prostate cancer (PCa) are urgently needed. Recent treatments of leukemias with chimeric antigen receptors (CARs) underline their impressive therapeutic potential. However CARs currently applied in the clinics cannot be repeatedly turned on and off potentially leading to severe life threatening side effects. To overcome these problems, we recently described a modular CAR technology termed UniCAR: UniCAR T cells are inert but can be turned on by application of one or multiple target modules (TMs)...
February 21, 2017: Oncotarget
https://www.readbyqxmd.com/read/28401244/integrated-68-ga-hbed-cc-psma-pet-mri-in-patients-with-suspected-recurrent-prostate-cancer
#13
Susanne Lütje, Joseph Cohnen, Benedikt Gomez, Johannes Grüneisen, Lino Sawicki, Herbert Rübben, Andreas Bockisch, Lale Umutlu, Thorsten D Pöppel, Axel Wetter
AIM: Evaluate the diagnostic accuracy of (68)Ga-labeled HBED-CC-PSMA-PET/MRI for detection of recurrent PCa in comparison to PET/CT. METHODS: 48 patients with suspected recurrent PCa underwent PET/CT after injection of the (68)Ga-HBED-CC-PSMA ligand followed by integrated PET/MRI. Image analysis was performed by nuclear medicine physicians and radiologists with respect to the detection of lymph node metastases, bone metastases and local recurrence of the tumour...
April 12, 2017: Nuklearmedizin. Nuclear Medicine
https://www.readbyqxmd.com/read/28396816/psma-pet-ct-positive-paget-disease-in-a-patient-with-newly-diagnosed-prostate-cancer-imaging-and-bone-biopsy-findings
#14
Michael Froehner, Marieta Toma, Klaus Zöphel, Vladimir Novotny, Michael Laniado, Manfred P Wirth
A 67-year-old man diagnosed with Gleason score 4 + 5 = 9 clinically localized prostate cancer with (68)Ga-labeled prostate-specific membrane antigen-targeted ligand positron emission tomography/computed tomography (PSMA-PET/CT) positive Paget bone disease is described. Immunohistochemical staining revealed weak PSMA positivity of the bone lesion supporting the hypothesis that neovasculature might explain positive PSMA-PET/CT findings in Paget disease.
2017: Case Reports in Urology
https://www.readbyqxmd.com/read/28368893/early-detection-of-bilateral-testicular-metastases-from-prostatic-adenocarcinoma-using-68ga-psma-ligand-pet-ct
#15
Desiree Weiberg, Herbert Radner, Thorsten Derlin, Walter F Thon
We present the case of a 76-year-old man with biochemical relapse after primary therapy for prostate cancer. Ga prostate-specific membrane antigen (PSMA) ligand PET/CT performed for localization of recurrent disease revealed bilateral metastases to the testes. Histopathologic evaluation after bilateral orchiectomy revealed testicular metastases. Metastases to the testes are rare and usually seen in advanced stages. Ga-PSMA ligand PET/CT is a highly sensitive and specific imaging method for the detection of primary and metastatic prostate cancer and has refined diagnostic approaches...
March 31, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28368889/image-of-the-month-multifocal-68ga-prostate-specific-membrane-antigen-ligand-uptake-in-the-skeleton-in-a-man-with-both-prostate-cancer-and-multiple-myeloma
#16
Isabel Rauscher, Tobias Maurer, Katja Steiger, Markus Schwaiger, Matthias Eiber
Ga prostate-specific membrane antigen (PSMA) HBED-CC PET/CT in a 65-year-old man with first diagnosis of prostate cancer (PC) and a history of multiple myeloma showing multifocal PSMA ligand uptake in the skeleton with corresponding osteolytic lesions in CT. Although osteolytic bone metastases are very rare in PC, PSMA expression in PET raised the suspicion of PC bone metastases. Bone marrow biopsy excluded PC metastases with immunohistochemistry showing endothelial expression of PSMA in small vessels within the myeloma...
March 31, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28368887/uptake-of-an-acrochordon-incidentally-detected-on-68ga-prostate-specific-membrane-antigen-pet-ct
#17
Gozde Daglioz Gorur, Turkay Hekimsoy, Serkan Isgoren, Aysun Sikar Akturk, Hakan Demir
Ga prostate-specific membrane antigen (PSMA) PET/CT is a promising tool for imaging of prostate cancer. Ga-PSMA PET/CT uptake of prostate cancer and its metastases are reflective of significant overexpression of PSMA. However, PSMA expression of benign neoplasms and nonprostate epithelial malignancies is not very well defined. We report a moderate Ga-PSMA uptake of an acrochordon (skin tag), which was incidentally found in a patient referred for staging prostate cancer. Acrochordon is a frequent, small, soft, skin-colored or hyperpigmented, benign, and usually pedunculated neoplasm of the skin...
March 31, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28368885/68ga-psma-pet-ct-uptake-in-intramuscular-myxoma-imitates-prostate-cancer-metastasis
#18
Helle D Zacho, Julie B Nielsen, Katja Dettmann, Sonja H Hjulskov, Lars J Petersen
Ga-PSMA PET/CT is becoming the most promising imaging modality for detecting recurrent prostate cancer. The modality has the advantage of being able to detect recurrent disease, even at very low prostate-specific antigen levels. However, several studies report Ga-PSMA uptake in tissue unrelated to prostate cancer. We present a 74-year-old man who underwent Ga-PSMA PET/CT for recurrent prostate cancer 5 years after radical prostatectomy. The Ga-PSMA PET/CT showed an intramuscular lesion with increased PSMA uptake in the left vastus medialis muscle...
March 31, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28349676/flourodeoxyglucose-positron-emission-tomography-scan-may-be-helpful-in-the-case-of-ductal-variant-prostate-cancer-when-prostate-specific-membrane-antigen-ligand-positron-emission-tomography-scan-is-negative
#19
Louise M McEwan, David Wong, John Yaxley
Gallium-68 prostate specific membrane antigen ligand (Ga-68 PSMA) positron emission tomography/computed tomography (PET/CT) scanning is emerging as a useful imaging modality for the staging of suspected and known recurrent or metastatic prostate cancer and in staging of newly diagnosed higher grade prostate cancer. However, we have observed at our institution that in some cases of the more aggressive ductal variant, Ga-68 PSMA uptake has sometimes been poor compared with prominent 18-flourodeoxyglucose (F-18 FDG) avidity seen in F-18 FDG PET/CT, which would suggest that FDG PET/CT scans are important in staging of ductal pattern prostate cancer...
March 28, 2017: Journal of Medical Imaging and Radiation Oncology
https://www.readbyqxmd.com/read/28346248/68ga-psma-pet-ct-in-osteosarcoma-in-fibrous-dysplasia
#20
Arun Sasikumar, Ajith Joy, M R A Pillai, Tony M Alex, Geetha Narayanan
Fibrous dysplasia (FD) is a benign bone lesion with a rare but potential for malignant transformation. Neither Tc-MDP nor F-FDG PET/CT can differentiate between FD and areas of malignant transformation in FD. We described a case of osteosarcoma developing in FD with selective uptake of tracer in malignant transformation areas demonstrated on a Ga-PSMA PET/CT scan. Our case highlights the ability of Ga-PSMA PET/CT to map tumor neoangiogenesis in osteosarcoma arising in FD, which can have potential implications in prognostication, possibility of antiangiogenesis-based therapeutic options, and in response assessment following chemotherapy...
March 24, 2017: Clinical Nuclear Medicine
keyword
keyword
5864
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"